Improving End of Life Care in Head and Neck Cancer

This study has been terminated.
(Lack of accrual)
Sponsor:
Information provided by (Responsible Party):
Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01632969
First received: June 29, 2012
Last updated: December 18, 2013
Last verified: December 2013

June 29, 2012
December 18, 2013
June 2012
June 2014   (final data collection date for primary outcome measure)
quality of care received by patients [ Time Frame: 1 year ] [ Designated as safety issue: No ]
To determine the perception of the family members of the quality of care received by patients with aerodigestive mucosal squamous cell carcinoma of the head and neck at the end of their lives. A survey will be administered to the families and next-of-kin of deceased patients. A recently validated survey instrument, the Family Assessment of Treatment at the End of life (FATE), is designed to assess treatment at the end of life based upon the responses of family members of the deceased (Finlay, Shreve et al. 2008).
Same as current
Complete list of historical versions of study NCT01632969 on ClinicalTrials.gov Archive Site
  • quality of death outcomes [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    To identify specific risk factors or interventions that might predict certain quality of death outcomes. A survey will be administered to the families and next-of-kin of deceased patients.A recently validated survey instrument, the Family Assessment of Treatment at the End of life (FATE), is designed to assess treatment at the end of life based upon the responses of family members of the deceased (Finlay, Shreve et al. 2008).
  • awareness among caregivers [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    To raise awareness among caregivers of the perspectives of family members of deceased patients, and of risk factors that might predict patient quality of death. This survey will be administered to the families and next-of-kin of deceased patients. A recently validated survey instrument, the Family Assessment of Treatment at the End of life (FATE), is designed to assess treatment at the end of life based upon the responses of family members of the deceased (Finlay, Shreve et al. 2008).
Same as current
Not Provided
Not Provided
 
Improving End of Life Care in Head and Neck Cancer
Improving End of Life Care in Head and Neck Cancer

The purpose of this study is to improve the quality of care provided for head and neck cancer patients. By better understanding the end of life experiences of dying patients and their families, the investigators hope to better anticipate and improve upon the experiences of future patients and their families.

Not Provided
Observational
Observational Model: Family-Based
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample

Deceased Head and Neck Surgery patients will be queried from Dataline and screened for eligibility. Interviews with family members and next of kin of deceased patients treated at MSKCC for noncutaneous squamous cell carcinomas of the upper aerodigestive tract will be conducted via telephone, employing the survey instruments.

  • The Families or Next of Kin of Patients Treated at MSKCC for Non-cutaneous Squamous Cell Carcinomas of the
  • Upper Aerodigestive Tract
Behavioral: The The Family Assessment of Treatment at the End of life (FATE ) survey
Study candidates will be contacted by mail with an initial contact letter with information explaining the study, and then will receive a follow-up phone call to discuss their participation in the study no later than 1 month following the posting of the initial contact letter. If a family member or next-of-kin chooses to participate, verbal informed consent will be obtained over the phone and a one-time telephone interview will be conducted.
families or next-of-kin of deceased patients
The families of deceased patients treated at MSKCC for non-cutaneous squamous cell carcinomas of the upper aerodigestive tract for whom contact information is available will be recruited by mail and by phone.
Intervention: Behavioral: The The Family Assessment of Treatment at the End of life (FATE ) survey
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
2
June 2014
June 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Head and neck cancer patients who received their treatment at MSKCC who have died of noncutaneous squamous cell carcinomas of the upper aerodigestive tract and for whom family / next of kin contact information is available.
  • Time of patient death must have been at least 6 months ago and no more than 4 years ago
  • Patient age at time of death must be over 21 years of age.
  • Those interviewed must be English-fluent.

Exclusion Criteria:

  • Non-English speaking interviewees
  • Next-of-kin who reported being unfamiliar with care received during the last month of life
  • Next-of-kin who did not identify themselves as one of the patient's primary social supports during the last month of life
  • Next-of-kin who were not physically present with the deceased at least once during the last week of his/her life
  • Next-of-kin under age 21
Both
21 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01632969
12-136
Not Provided
Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
Not Provided
Principal Investigator: Snehal Patel, MD Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP